MMSI / Merit Medical Systems, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Agreement and Plan of Merger by and among Merit Medical Systems, Inc., Biolife Transaction Sub, LLC, Biolife, L.L.C., and Shareholder Representative Services LLC, dated as of May 16, 2025.

Exhibit 2.1 Execution Version AGREEMENT AND PLAN OF MERGER by and among MERIT MEDICAL SYSTEMS, INC., and BIOLIFE TRANSACTION SUB, LLC, and BIOLIFE, L.L.C., and SHAREHOLDER REPRESENTATIVE SERVICES LLC AS MEMBER REPRESENTATIVE dated as of May 16, 2025 i TABLE OF CONTENTS Page ARTICLE I DEFINITIONS .......................................................................................................

2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as

Exhibit 99.2 1 Merit Medical Investor Call July 30, 2025 Second Quarter 2025 Results Fred Lampropoulos Chairman, CEO and President Raul Parra CFO 2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amen

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 0-18592 MERI

Three Months Ended

Exhibit 99.1 Contacts: PR/Media Inquiries: Sarah Comstock Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC ICR Healthcare +1-801-432-2864 +1-443-213-0509 [email protected] [email protected] FOR IMMEDIATE RELEASE MERIT MEDICAL REPORTS SECOND QUARTER 2025 RESULTS AND UPDATES FULL-YEAR GUIDANCE Highlights† ● Reported revenue of $382.5 million, up 13.2% ● Constant curre

Form of Restricted Stock Unit Award Agreement, dated May 15, 2025, by and between Merit Medical Systems, Inc. and each of the following individuals: Lonny J. Carpenter, Stephen C. Evans, David K. Floyd, Thomas J. Gunderson, Laura S. Kaiser, Michael R. McDonnell, F. Ann Millner, Silvia M. Perez and Lynne N. Ward.

Exhibit 10.1 MERIT MEDICAL SYSTEMS, INC 2018 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT This Restricted Stock Unit Award Agreement (this “Award Agreement”), dated effective as May 15, 2025 (the “Grant Date”), is made by and between Merit Medical Systems, Inc. (the “Company”), and , a director of the Company (“you”). 1. Award of Restricted Stock Units The Company hereby grants t

Corporate Policy on Insider Trading (revised May 15, 2025).

Exhibit 19.1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 30, 2025 Merit Medical Syste

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 30, 2025 Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of (Commission (I.R.S. Employer i

Three months Ended

EXHIBIT 99.1 Merit Medical Names Martha Aronson as New President and Chief Executive Officer Fred Lampropoulos will continue to serve as Chairman of Merit’s Board of Directors Merit announces preliminary unaudited revenue for the quarter ended June 30, 2025 SOUTH JORDAN, Utah, July 7, 2025 (GLOBE NEWSWIRE) – Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, anno

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 7, 2025 Merit Medical System

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 7, 2025 Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of (Commission (I.R.S. Employer in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K ☒ Annual Report Pursuant to Section 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 ☐ Transition Report Pursuant to Section 15(

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K ☒ Annual Report Pursuant to Section 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 OR ☐ Transition Report Pursuant to Section 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-18592 A. Full title of the plan and the addre

Exhibit 1.01 - Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form.

Merit Medical Systems, Inc. Conflict Minerals Report For Calendar Year 2024 Merit Medical Systems, Inc. (“Merit,” the “Company,” “we,” “us,” or “our”) submits this Conflict Minerals Report for the period January 1 to December 31, 2024, pursuant to Rule 13p-1 under the Securities Exchange Act of 1934, as amended (the “Rule”). The Rule was adopted by the Securities and Exchange Commission (the “SEC”

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report MERIT MEDICAL SYSTEMS, INC. (Exact name of the registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 1600 West Merit Parkway, South Jordan, Utah 84095 (Address of principal e

Updated Guidance

EXHIBIT 99.1 Contacts: PR/Media Inquiries: Sarah Comstock Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC ICR Healthcare +1-801-432-2864 +1-443-213-0509 [email protected] [email protected] Merit Medical Acquires Biolife Delaware, L.L.C. ● Acquired business offers the StatSeal® and WoundSeal® products, which provide hemostasis solutions that complement the wide rang

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 16, 2025 Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of (Commission (I.R.S. Employer in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 14, 2025 Merit Medical System

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 14, 2025 Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of (Commission (I.R.S. Employer in

Restricted Stock Unit Award Agreement, dated February 28, 2025, by and between Merit Medical Systems, Inc. and Brian Lloyd.†

Exhibit 10.10 MERIT MEDICAL SYSTEMS, INC 2018 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT This Restricted Stock Unit Award Agreement (this “Award Agreement”), dated effective as of February 28, 2025 (the “Grant Date”), is made by and between Merit Medical Systems, Inc. (the “Company”), and Brian Lloyd, an employee of the Company (“you”). 1. Award of Restricted Stock Units The Co

2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as

Exhibit 99.2 1 Merit Medical Investor Call April 24, 2025 First Quarter 2025 Results Fred Lampropoulos Chairman, CEO and President Raul Parra CFO 2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amen

Rule 10b5-1 Trading Plan, dated February 28, 2025, between Michael R. McDonnell and Morgan Stanley Smith Barney LLC.

Exhibit 10.2 Page 1 of 23 E*TRADE from Morgan Stanley Rule 10b5-1 Trading Plan (Stock and Options) This trading plan (this “Plan”) completed and executed by MICHAEL R MCDONNELL (“Client”) on February 28, 2025 (the “Adoption Date”) between Client and Morgan Stanley Smith Barney LLC (“MSSB”) acting as agent for Client shall be effective as of the date on which MSSB executes this Plan (the “Effective

Restricted Stock Unit Award Agreement, dated February 28, 2025, by and between Merit Medical Systems, Inc. and Neil Peterson.†

Exhibit 10.11 MERIT MEDICAL SYSTEMS, INC 2018 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT This Restricted Stock Unit Award Agreement (this “Award Agreement”), dated effective as of February 28, 2025 (the “Grant Date”), is made by and between Merit Medical Systems, Inc. (the “Company”), and Neil Peterson, an employee of the Company (“you”). 1. Award of Restricted Stock Units The

Performance Stock Unit Award Agreement (Three Year Performance Period), dated February 28, 2025, by and between Merit Medical Systems, Inc. and Neil Peterson.†

Exhibit 10.6 MERIT MEDICAL SYSTEMS, INC 2018 LONG-TERM INCENTIVE PLAN Performance Stock Unit Award Agreement (Three Year Performance Period) This Performance Stock Unit Award Agreement (this “Award Agreement”), dated as of February 28, 2025 (the “Grant Date”), is made by and between Merit Medical Systems, Inc. (the “Company”), and Neil Peterson, an employee of the Company (“you”). 1. Award of Perf

Restricted Stock Unit Award Agreement, dated February 28, 2025, by and between Merit Medical Systems, Inc. and Mike Voigt.†

Exhibit 10.12 MERIT MEDICAL SYSTEMS, INC 2018 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT This Restricted Stock Unit Award Agreement (this “Award Agreement”), dated effective as of February 28, 2025 (the “Grant Date”), is made by and between Merit Medical Systems, Inc. (the “Company”), and Mike Voigt, an employee of the Company (“you”). 1. Award of Restricted Stock Units The Com

Performance Stock Unit Award Agreement (Three Year Performance Period), dated February 28, 2025, by and between Merit Medical Systems, Inc. and Fred Lampropoulos.†

Exhibit 10.3 MERIT MEDICAL SYSTEMS, INC 2018 LONG-TERM INCENTIVE PLAN Performance Stock Unit Award Agreement (Three Year Performance Period) This Performance Stock Unit Award Agreement (this “Award Agreement”), dated as of February 28, 2025 (the “Grant Date”), is made by and between Merit Medical Systems, Inc. (the “Company”), and Fred Lampropoulos, an employee of the Company (“you”). 1. Award of

Three Months Ended

Exhibit 99.1 Contacts: PR/Media Inquiries: Sarah Comstock Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC ICR Healthcare +1-801-432-2864 +1-443-213-0509 [email protected] [email protected] FOR IMMEDIATE RELEASE MERIT MEDICAL REPORTS FIRST QUARTER 2025 RESULTS AND UPDATES FULL-YEAR GUIDANCE First Quarter Highlights† ● Reported revenue of $355.4 million, up 9.8% ● Co

Restricted Stock Unit Award Agreement, dated February 28, 2025, by and between Merit Medical Systems, Inc. and Raul Parra.†

Exhibit 10.9 MERIT MEDICAL SYSTEMS, INC 2018 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT This Restricted Stock Unit Award Agreement (this “Award Agreement”), dated effective as of February 28, 2025 (the “Grant Date”), is made by and between Merit Medical Systems, Inc. (the “Company”), and Raul Parra, an employee of the Company (“you”). 1. Award of Restricted Stock Units The Comp

Rule 10b5-1 Trading Plan, dated February 28, 2025, between David K. Floyd and Charles Schwab & Co., Inc.

Exhibit 10.1

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 24, 2025 Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of (Commission (I.R.S. Employer

Performance Stock Unit Award Agreement (Three Year Performance Period), dated February 28, 2025, by and between Merit Medical Systems, Inc. and Raul Parra.†

Exhibit 10.4 MERIT MEDICAL SYSTEMS, INC 2018 LONG-TERM INCENTIVE PLAN Performance Stock Unit Award Agreement (Three Year Performance Period) This Performance Stock Unit Award Agreement (this “Award Agreement”), dated as of February 28, 2025 (the “Grant Date”), is made by and between Merit Medical Systems, Inc. (the “Company”), and Raul Parra, an employee of the Company (“you”). 1. Award of Perform

Performance Stock Unit Award Agreement (Three Year Performance Period), dated February 28, 2025, by and between Merit Medical Systems, Inc. and Mike Voigt.†

Exhibit 10.7 MERIT MEDICAL SYSTEMS, INC 2018 LONG-TERM INCENTIVE PLAN Performance Stock Unit Award Agreement (Three Year Performance Period) This Performance Stock Unit Award Agreement (this “Award Agreement”), dated as of February 28, 2025 (the “Grant Date”), is made by and between Merit Medical Systems, Inc. (the “Company”), and Mike Voigt, an employee of the Company (“you”). 1. Award of Perform

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 0-18592 MER

Performance Stock Unit Award Agreement (Three Year Performance Period), dated February 28, 2025, by and between Merit Medical Systems, Inc. and Brian Lloyd.†

Exhibit 10.5 MERIT MEDICAL SYSTEMS, INC 2018 LONG-TERM INCENTIVE PLAN Performance Stock Unit Award Agreement (Three Year Performance Period) This Performance Stock Unit Award Agreement (this “Award Agreement”), dated as of February 28, 2025 (the “Grant Date”), is made by and between Merit Medical Systems, Inc. (the “Company”), and Brian Lloyd, an employee of the Company (“you”). 1. Award of Perfor

Restricted Stock Unit Award Agreement, dated February 28, 2025, by and between Merit Medical Systems, Inc. and Fred Lampropoulos.†

Exhibit 10.8 MERIT MEDICAL SYSTEMS, INC 2018 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT This Restricted Stock Unit Award Agreement (this “Award Agreement”), dated effective as of February 28, 2025 (the “Grant Date”), is made by and between Merit Medical Systems, Inc. (the “Company”), and Fred Lampropoulos, an employee of the Company (“you”). 1. Award of Restricted Stock Units T

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A ☒Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 ☐Transition report pursuant to Secti

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A ☒Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 or ☐Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 0-18592 MERIT M

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [x] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. XX)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. XX) Filed by the Registrant [x] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted

Rule 10b5-1 Trading Plan, dated November 6, 2024, between Neil W. Peterson and Morgan Stanley Smith Barney LLC.

Exhibit 10.78 Page 1 of 24 E*TRADE from Morgan Stanley Rule 10b5-1 Trading Plan (Stock and Options) This trading plan (this “Plan”) completed and executed by NEIL W PETERSON November 6, 2024 (“Client”) on (the “Adoption Date”) between Client and Morgan Stanley Smith Barney LLC (“MSSB”) acting as agent for Client shall be effective as of the date on which MSSB executes this Plan (the “Effective Dat

2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This release contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as a

Exhibit 99.2 1 Merit Medical Investor Call February 25, 2025 Fourth Quarter 2024 Results Fred Lampropoulos Chairman, CEO and President Raul Parra CFO 2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This release contains forward-looking statements within the meaning of the Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as a

Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

EXHIBIT 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Merit Medical Systems, Inc. (“Merit” “we” “us” or “our”) has one class of securities, our common stock, registered under Section 12 of the Securities Exchange Act of 1934, as amended. The general terms and provisions of our common stock are summarized below. The below sum

Three Months Ended

Exhibit 99.1 Contacts: PR/Media Inquiries: Sarah Comstock Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC ICR Healthcare +1-801-432-2864 +1-443-213-0509 [email protected] [email protected] FOR IMMEDIATE RELEASE MERIT MEDICAL REPORTS FOURTH QUARTER AND FULL YEAR 2024 RESULTS AND ISSUES FISCAL YEAR 2025 GUIDANCE Fourth Quarter Highlights† ● Reported revenue of $355.2

Subsidiaries of Merit Medical Systems, Inc.

Exhibit 21 SUBSIDIARIES OF MERIT MEDICAL SYSTEMS, INC. Subsidiary Name Jurisdiction of Incorporation/Organization Merit Medical Australia Pty Ltd. Australia Merit Medical Austria GmbH Austria Merit Medical Belgium Sprl (BVBA) Belgium Merit Medical Comercialização, Distribuição, Importação e Exportação de Produtos Hospitalares LTDA. Brazil Merit Medical Canada Ltd. Canada Merit Medical Beijing Co.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2024 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 0-18592 MERIT M

Separation Agreement and Release of All Claims dated December 16, 2024 betewen Merit Medical Systems, Inc. and Joseph C. Wright.†

Exhibit 10.68 This document affects your legal rights. You are advised to consult with an attorney or other counsel of your choice prior to signing this Agreement. SEPARATION AGREEMENT AND RELEASE OF ALL CLAIMS THIS SEPARATION AGREEMENT AND RELEASE OF ALL CLAIMS (the “Agreement”) is entered into between Merit Medical Systems, Inc., a Utah corporation (“Employer”), and Joseph C. Wright (“Employee”)

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 25, 2025 Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of (Commission (I.R.S. Employ

Corporate Policy on Insider Trading

Exhibit 19.1 1 MERIT MEDICAL SYSTEMS, INC. CORPORATE POLICY ON INSIDER TRADING (Revised May 18, 2023) In the course of employment with Merit Medical Systems, Inc. (the “ Company”), including employment with a subsidiary of the Company, directors, officers and employees may come into possession of confidential and highly sensitive information concerning the Company. Sensitive information has a pote

Merit Medical Systems Wrapsody Investor Conference Call Remarks

EXHIBIT 99.1 Merit Medical Systems Wrapsody Investor Conference Call Remarks Operator: Please standby. Welcome to the Merit Medical Systems Wrapsody Investor Conference Call. At this time, all participants have been placed in listen-only mode. Please note that this conference call is being recorded and that the recording will be available on the Company’s website for replay shortly. I would now li

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 28, 2025 Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of (Commission (I.R.S. Employe

MERIT MEDICAL ANNOUNCES PRELIMINARY UNAUDITED REVENUE FOR THE YEAR ENDED DECEMBER 31, 2024 AND PLANS TO ANNOUNCE FOURTH QUARTER AND YEAR END 2024 RESULTS AND ISSUE FISCAL YEAR 2025 GUIDANCE ON FEBRUARY 25, 2025

EXHIBIT 99.1 Contacts: PR/Media Inquiries: Sarah Comstock Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC Westwicke - ICR +1-801-432-2864 +1-443-213-0509 [email protected] [email protected] FOR IMMEDIATE RELEASE MERIT MEDICAL ANNOUNCES PRELIMINARY UNAUDITED REVENUE FOR THE YEAR ENDED DECEMBER 31, 2024 AND PLANS TO ANNOUNCE FOURTH QUARTER AND YEAR END 2024 RESULTS AND I

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 13, 2025 Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of (Commission (I.R.S. Employe

Regulation FD Disclosure, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 16, 2024 Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of (Commission (I.R.S. Employ

PR/Media Inquiries:

EX-99.1 2 mmsi-20241216xex99d1.htm EX-99.1 EXHIBIT 99.1 Contacts: PR/Media Inquiries: Sarah Comstock Merit Medical +1-801-432-2864 [email protected] Merit Medical Announces Resignation of President, Joseph Wright SOUTH JORDAN, Utah, December 16, 2024 (GLOBE NEWSWIRE) - Merit Medical Systems, Inc. (NASDAQ: MMSI) (“Merit” or the “Company”), a global leader of healthcare technology, today anno

MMSI / Merit Medical Systems, Inc. / WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 4)* Merit Medical Systems Inc (Name of Issuer) Common Stock (Title of Class of Securities) 589889104 (CUSIP Number) September 30, 2024 (Date of

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 1, 2024 Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of (Commission (I.R.S. Employe

PR/Media Inquiries:

EXHIBIT 99.1 Contacts: PR/Media Inquiries: Sarah Comstock Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC Westwicke - ICR +1-801-432-2864 +1-443-213-0509 [email protected] [email protected] Merit Medical Completes Acquisition of Lead Management Portfolio from Cook Medical SOUTH JORDAN, Utah, November 1, 2024 (GLOBE NEWSWIRE) - Merit Medical Systems, Inc. (NASDAQ: MMSI)

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 30, 2024 Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of (Commission (I.R.S. Employe

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 0-18592

2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation and any accompanying management commentary contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E

Exhibit 99.2 1 Merit Medical Investor Call October 30, 2024 Third Quarter 2024 Results Fred Lampropoulos Chairman and CEO Raul Parra CFO 2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation and any accompanying management commentary contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securi

Three Months Ended

Exhibit 99.1 Contacts: PR/Media Inquiries: Sarah Comstock Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC Westwicke – ICR +1-801-432-2864 +1-443-213-0509 [email protected] [email protected] FOR IMMEDIATE RELEASE MERIT MEDICAL REPORTS THIRD QUARTER 2024 RESULTS AND RAISES FULL-YEAR GUIDANCE Third Quarter 2024 Highlights† ● Reported revenue of $339.8 million, up 7.8% ● C

Asset Purchase Agreement, dated September 16, 2024, by and between Merit Medical Systems, Inc. and Cook Medical Holdings LLC.

Exhibit 2.1 EXHIBIT 2.1 Execution Version CERTAIN INFORMATION CONTAINED IN THIS DOCUMENT HAS BEEN EXCLUDED BECAUSE IT (I) IS NOT MATERIAL AND (II) IS THE TYPE OF INFORMATION THAT MERIT MEDICAL SYSTEMS, INC. TREATS AS PRIVATE OR CONFIDENTIAL. THE EXCULDED INFORMATION IS IDENTIFIED BY THE FOLLOWING MARK: [* * *] ASSET PURCHASE AGREEMENT by and between COOK MEDICAL HOLDINGS LLC as Seller and MERIT ME

PR/Media Inquiries:

EXHIBIT 99.2 Contacts: PR/Media Inquiries: Sarah Comstock Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC Westwicke - ICR +1-801-432-2864 +1-443-213-0509 [email protected] [email protected] Merit Medical’s WRAPSODY WAVE Trial Demonstrates Superior Patency versus Standard of Care in AV Fistula Patients In the US pivotal trial, WRAPSODY achieved 89.8% target lesion prima

Updated Guidance(1)

EXHIBIT 99.1 Contacts: PR/Media Inquiries: Sarah Comstock Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC Westwicke - ICR +1-801-432-2864 +1-443-213-0509 [email protected] [email protected] Merit Medical Signs Agreement to Purchase Lead Management Portfolio from Cook Medical® ● Asset acquisition of Cook Medical’s end-to-end lead management product portfolio strengthens

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): September 16, 2024 Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of (Commission (I.R.S. Emplo

Calculation of filing fee tables

Calculation of Filing Fee Tables S-8 MERIT MEDICAL SYSTEMS INC Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, no par value Other 3,000,000 $ 92.

As filed with the Securities and Exchange Commission on August 29, 2024

As filed with the Securities and Exchange Commission on August 29, 2024 Registration No.

August 23, 2024

August 23, 2024 Securities and Exchange Commission Division of Corporate Finance Disclosure Review Program 100 F Street, NE Washington, D.

2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation and any accompanying management commentary contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E

Exhibit 99.3 1 Merit Medical Investor Call August 1, 2024 Second Quarter 2024 Results Fred Lampropoulos Chairman and CEO Raul Parra CFO 2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation and any accompanying management commentary contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securit

Three Months Ended

Exhibit 99.1 Contacts: PR/Media Inquiries: Teresa Johnson Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC Westwicke – ICR +1-801-208-4295 +1-443-213-0509 [email protected] [email protected] FOR IMMEDIATE RELEASE MERIT MEDICAL REPORTS SECOND QUARTER 2024 RESULTS AND RAISES FULL-YEAR GUIDANCE Second Quarter 2024 Highlights† ● Reported revenue of $338.0 million, up 5.6% ● Const

Asset Purchase Agreement, dated July 1, 2024, by and between Merit Medical Systems, Inc. and Endogastric Solutions, Inc.

EXHIBIT 2.1 ASSET PURCHASE AGREEMENT BY AND BETWEEN MERIT MEDICAL SYSTEMS, INC. AND ENDOGASTRIC SOLUTIONS, INC. Dated as of July 1, 2024 TABLE OF CONTENTS Article 1 THE TRANSACTIONs 1.1 Purchased Assets‌1 1.2 Excluded Assets‌2 1.3 Assumed Liabilities‌2 1.4 Excluded Liabilities‌3 1.5 Non-Assignable Assets‌3 Article 2 CONSIDERATION FOR TRANSFER 2.1 Purchase Price and Assumption of Assumed Liabilitie

August 1, 2024

August 1, 2024 Securities and Exchange Commission Division of Corporate Finance Office of Industrial Applications and Services 100 F Street, NE Washington, D.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 0-18592 MERI

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): August 1, 2024 Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of (Commission (I.R.S. Employer

Merit Medical to Present 6-Month Outcomes from Randomized Arm of WRAPSODY™ Arteriovenous Access Efficacy (WAVE) Pivotal Study at Two Upcoming Medical Meetings

Exhibit 99.2 Merit Medical to Present 6-Month Outcomes from Randomized Arm of WRAPSODY™ Arteriovenous Access Efficacy (WAVE) Pivotal Study at Two Upcoming Medical Meetings SOUTH JORDAN, Utah, August 1, 2024 (GLOBE NEWSWIRE) - Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced plans to release findings from its WAVE study. A pivotal, international,

Form of Restricted Stock Unit Award Agreement, dated May 16, 2024, by and between Merit Medical Systems, Inc. and each of the following individuals: Lonny J. Carpenter, Stephen C. Evans, David K. Floyd, Thomas J. Gunderson, Laura S. Kaiser, Michael R. McDonnell, F. Ann Millner, Lynne N. Ward and Silvia M. Perez.*†

EXHIBIT 10.2 MERIT MEDICAL SYSTEMS, INC 2018 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT This Restricted Stock Unit Award Agreement (this “Award Agreement”), dated effective as May 16, 2024 (the “Grant Date”), is made by and between Merit Medical Systems, Inc. (the “Company”), and , a director of the Company (“you”). 1. Award of Restricted Stock Units The Company hereby grants t

July 12, 2024

July 12, 2024 Securities and Exchange Commission Division of Corporate Finance Office of Industrial Applications and Services 100 F Street, NE Washington, D.

Regulation FD Disclosure, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 1, 2024 Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of (Commission (I.R.S. Employer in

Contacts: PR/Media Inquiries: Sarah Comstock Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC Westwicke - ICR +1-801-432-2864 +1-443-213-0509 [email protected] [email protected]

EXHIBIT 99.1 Contacts: PR/Media Inquiries: Sarah Comstock Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC Westwicke - ICR +1-801-432-2864 +1-443-213-0509 [email protected] [email protected] Merit Medical Announces Asset Purchase Agreement with EndoGastric Solutions, Inc.® ● Asset acquisition expands Merit’s endoscopy portfolio with a minimally invasive solution for pat

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K ☒ Annual Report Pursuant to Section 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 ☐ Transition Report Pursuant to Section 15(

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K ☒ Annual Report Pursuant to Section 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 OR ☐ Transition Report Pursuant to Section 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 0-18592 A. Full title of the plan and the addre

Exhibit 1.01 - Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form.

CONFLICT MINERALS REPORT MERIT MEDICAL SYSTEMS, INC. YEAR ENDED DECEMBER 31, 2023 This Conflict Minerals Report (this “Report”) for the year ended December 31, 2023, is presented by Merit Medical Systems, Inc. (“Merit”) to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the “Rule”). The Rule was adopted by the Securities and Exchange Commission (“SEC”) to implement reporting and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report MERIT MEDICAL SYSTEMS, INC. (Exact name of the registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 1600 West Merit Parkway, South Jordan, Utah 84095 (Address of principal e

May 24, 2024

May 24, 2024 Securities and Exchange Commission Division of Corporate Finance Office of Industrial Applications and Services 100 F Street, NE Washington, D.

Indemnification Agreement dated May 15, 2024 between Merit Medical Systems, Inc. and Silvia M. Perez

EXHIBIT 10.1 INDEMNIFICATION AGREEMENT This Indemnification Agreement (the “Agreement”) is made as of May 15, 2024, by and between Merit Medical Systems, Inc., a Utah corporation (“Company”), and Silvia M. Perez, an individual (“Indemnitee”). RECITALS A.The Company is aware that because of the increased exposure to litigation costs, talented and experienced persons are increasingly reluctant to se

Summary report: Litera Compare for Word 11.8.0.56 Document comparison done on 5/16/2024 8:45:26 AM

EXHIBIT 99.1 Merit Medical Shareholders Elect Silvia M. Perez as New Director Experienced healthcare veteran brings a broad background spanning clinical, regulatory, operations, marketing, and business leadership to Merit’s Board of Directors. SOUTH JORDAN, Utah, May 16, 2024 (GLOBE NEWSWIRE) - Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced th

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 15, 2024 Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of (Commission (I.R.S. Employer in

Fourth Amended and Restated Bylaws.*

EXHIBIT 3.1 FOURTH AMENDED AND RESTATED BYLAWS OF MERIT MEDICAL SYSTEMS, INC. May 16, 2024 ARTICLE I. OFFICES The principal office of the Corporation in the State of Utah shall be located in the City of South Jordan, County of Salt Lake. The Corporation may have such other offices, either within or without the State of Utah, as the Board of Directors may designate or as the business of the Corpora

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 15, 2024 Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of (Commission (I.R.S. Employer in

Merit Medical Executive Leadership Team Update Joe Wright Appointed President Expands Deep Bench of Leadership Team Talent; Supports “Continued Growth Initiatives” Program

Exhibit 99.1 Merit Medical Executive Leadership Team Update Joe Wright Appointed President Expands Deep Bench of Leadership Team Talent; Supports “Continued Growth Initiatives” Program SOUTH JORDAN, Utah, May 15, 2024 (GLOBE NEWSWIRE) - Merit Medical Systems, Inc. (NASDAQ: MMSI), a global leader of healthcare technology, today announced the appointment of Joe Wright as President, effective immedia

May 8, 2024

May 8, 2024 Securities and Exchange Commission Division of Corporate Finance Office of Industrial Applications and Services 100 F Street, NE Washington, D.

Restricted Stock Unit Award Agreement, dated March 8, 2024, by Merit Medical Systems, Inc. and Mike Voigt.*†

Exhibit 10.8 MERIT MEDICAL SYSTEMS, INC 2018 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT This Restricted Stock Unit Award Agreement (this “Award Agreement”), dated effective as of March 8, 2024 (the “Grant Date”), is made by and between Merit Medical Systems, Inc. (the “Company”), and Mike Voigt, an employee of the Company (“you”). 1. Award of Restricted Stock Units The Company

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 0-18592 MER

Rule 10b5-1 Trading Plan, dated March 11, 2024, between Neil W. Peterson and Morgan Stanley Smith Barney LLC.

Exhibit 10.1 Page 1 of 23 E*TRADE from Morgan Stanley Rule 10b5-1 Trading Plan (Stock and Options) This trading plan (this “Plan”) completed and executed by NEIL W PETERSON (“Client”) on March 11, 2024 (the “Adoption Date”) between Client and Morgan Stanley Smith Barney LLC (“MSSB”) acting as agent for Client shall be effective as of the date on which MSSB executes this Plan (the “Effective Date”)

MERIT MEDICAL REPORTS RESULTS FOR FIRST QUARTER ENDED MARCH 31, 2024

Exhibit 99.1 Contacts: PR/Media Inquiries: Teresa Johnson Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC Westwicke – ICR +1-801-208-4295 +1-443-213-0509 [email protected] [email protected] FOR IMMEDIATE RELEASE MERIT MEDICAL REPORTS RESULTS FOR FIRST QUARTER ENDED MARCH 31, 2024 ● Q1 2024 reported revenue of $323.5 million, up 8.7% compared to Q1 2023 ● Q1 2024 constant cur

Form of Restricted Stock Unit Award Agreement, dated March 4, 2024, by Merit Medical Systems, Inc. and each of the following individuals: Raul Parra, Neil Peterson, Brian Lloyd and Joe Wright.*†

Exhibit 10.7 MERIT MEDICAL SYSTEMS, INC 2018 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT This Restricted Stock Unit Award Agreement (this “Award Agreement”), dated effective as of March 4, 2024 (the “Grant Date”), is made by and between Merit Medical Systems, Inc. (the “Company”), and , an employee of the Company (“you”). 1. Award of Restricted Stock Units The Company hereby gra

Performance Stock Unit Award Agreement (Three Year Performance Period), dated March 4, 2024, by Merit Medical Systems, Inc. and Mike Voigt.*†

Exhibit 10.5 MERIT MEDICAL SYSTEMS, INC 2018 LONG-TERM INCENTIVE PLAN Performance Stock Unit Award Agreement (Three Year Performance Period) This Performance Stock Unit Award Agreement (this “Award Agreement”), dated as of March 4, 2024 (the “Grant Date”), is made by and between Merit Medical Systems, Inc. (the “Company”), and Mike Voigt, an employee of the Company (“you”). 1. Award of Performance

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 30, 2024 Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of (Commission (I.R.S. Employer

2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation and any accompanying management commentary include “forward-looking statements,” as defined within applicable securities laws and regulations. All statements in this presen

Exhibit 99.2 1 Merit Medical Investor Call April 30, 2024 First Quarter 2024 Results Fred Lampropoulos Chairman and CEO Raul Parra CFO 2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation and any accompanying management commentary include “forward-looking statements,” as defined within applicable securities laws and regulations. All statements in this presentation, other t

Performance Stock Unit Award Agreement (Three Year Performance Period), dated March 4, 2024, by and between Merit Medical Systems, Inc. and Fred Lampropoulos.*†

Exhibit 10.3 MERIT MEDICAL SYSTEMS, INC 2018 LONG-TERM INCENTIVE PLAN Performance Stock Unit Award Agreement (Three Year Performance Period) This Performance Stock Unit Award Agreement (this “Award Agreement”), dated as of March 4, 2024 (the “Grant Date”), is made by and between Merit Medical Systems, Inc. (the “Company”), and Fred Lampropoulos, an employee of the Company (“you”). 1. Award of Perf

Form of Performance Stock Unit Award Agreement (Three Year Performance Period), dated March 4, 2024, by Merit Medical Systems, Inc. and each of the following individuals: Raul Parra, Neil Peterson, Brian Lloyd and Joe Wright.*†

Exhibit 10.4 MERIT MEDICAL SYSTEMS, INC 2018 LONG-TERM INCENTIVE PLAN Performance Stock Unit Award Agreement (Three Year Performance Period) This Performance Stock Unit Award Agreement (this “Award Agreement”), dated as of March 4, 2024 (the “Grant Date”), is made by and between Merit Medical Systems, Inc. (the “Company”), and , an employee of the Company (“you”). 1. Award of Performance Stock Uni

Restricted Stock Unit Award Agreement, dated March 9, 2024, by and between Merit Medical Systems, Inc. and Fred Lampropoulos.*†

Exhibit 10.6 MERIT MEDICAL SYSTEMS, INC 2018 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT This Restricted Stock Unit Award Agreement (this “Award Agreement”), dated effective as of March 9, 2024 (the “Grant Date”), is made by and between Merit Medical Systems, Inc. (the “Company”), and Fred Lampropoulos, an employee of the Company (“you”). 1. Award of Restricted Stock Units The C

Rule 10b5-1 Trading Plan, dated March 15, 2024, between Raul Parra and Morgan Stanley Smith Barney LLC.

Exhibit 10.2 Page 1 of 23 E*TRADE from Morgan Stanley Rule 10b5-1 Trading Plan (Stock and Options) This trading plan (this “Plan”) completed and executed by RAUL PARRA (“Client”) on March 15, 2024 (the “Adoption Date”) between Client and Morgan Stanley Smith Barney LLC (“MSSB”) acting as agent for Client shall be effective as of the date on which MSSB executes this Plan (the “Effective Date”). A.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [x] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. XX)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. XX) Filed by the Registrant [x] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted

2023 ANNUAL REPORT CONTINUED GROWTH INITIATIVES A MESSAGE FROM THE CHAIRMAN & CEO DEAR SHAREHOLDERS, In 2023, Merit completed the final year of the Foundations for Growth program, delivering or exceeding each of the financial targets we outlined for

2023 ANNUAL REPORT CONTINUED GROWTH INITIATIVES A MESSAGE FROM THE CHAIRMAN & CEO DEAR SHAREHOLDERS, In 2023, Merit completed the final year of the Foundations for Growth program, delivering or exceeding each of the financial targets we outlined for the three-year period ended December 31, 2023.

Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

EXHIBIT 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Merit Medical Systems, Inc. (“Merit” “we” “us” or “our”) has one class of securities, our common stock, registered under Section 12 of the Securities Exchange Act of 1934, as amended. The general terms and provisions of our common stock are summarized below. The below sum

MERIT MEDICAL INTRODUCES “CONTINUED GROWTH INITIATIVES” PROGRAM AND FINANCIAL TARGETS FOR THREE-YEAR PERIOD ENDING DECEMBER 31, 2026

Exhibit 99.3 Exhibit 99.1 Contacts: PR/Media Inquiries: Teresa Johnson Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC Westwicke - ICR +1-801-208-4295 +1-443-213-0509 [email protected] [email protected] FOR IMMEDIATE RELEASE MERIT MEDICAL INTRODUCES “CONTINUED GROWTH INITIATIVES” PROGRAM AND FINANCIAL TARGETS FOR THREE-YEAR PERIOD ENDING DECEMBER 31, 2026 SOUTH JORDAN, Utah,

Subsidiaries of Merit Medical Systems, Inc.

Exhibit 21 SUBSIDIARIES OF MERIT MEDICAL SYSTEMS, INC. Subsidiary Name Jurisdiction of Incorporation/Organization Merit Medical Australia Pty Ltd. Australia ITL Healthcare Pty Ltd. Australia Merit Medical Austria GmbH Austria Merit Medical Belgium Sprl Belgium Merit Medical Comercialização, Distribuição, Importação e Exportação de Produtos Hospitalares LTDA. Brazil Merit Medical Canada Ltd. Canada

Rule 10b5-1 Trading Plan, dated August 7, 2023, between F. Ann Millner and E*TRADE Securities LLC.

Exhibit 10.69 Page 1 of 23 E*TRADE Securities LLC Rule 10b5-1 Trading Plan (Stock and Options) This trading plan (this “Plan”) completed and executed by F ANN MILLNER (“Client”) on August 7, 2023 (the “Adoption Date”) between Client and E*TRADE Securities LLC (“E*TRADE”) acting as agent for Client shall be effective as of the date on which E*TRADE executes this Plan (the “Effective Date”). A. Reci

First Amendment to the Fourth Amended and Restated Credit Agreement dated December 5, 2023, by and among certain subsidiaries of Merit Medical Systems, Inc., Wells Fargo Bank, National Association, as administrative agent for Lenders, Bank of America, N.A., HSBC Bank USA, National Association, U.S. Bank National Association, Truist Bank, TD Bank, N.A., Huntington National Bank, and Regions Bank.

Exhibit 10.68 EXECUTION VERSION 1818774707 FIRST AMENDMENT TO FOURTH AMENDED AND RESTATED CREDIT AGREEMENT Dated as of December 5, 2023 This FIRST AMENDMENT TO FOURTH AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”) is by and among MERIT MEDICAL SYSTEMS, INC., a Utah corporation (the “Borrower”), certain subsidiaries of the Borrower party hereto (the “Subsidiary Guarantors”), the lenders w

2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation and any accompanying management commentary include “forward-looking statements,” as defined within applicable securities laws and regulations. All statements in this presen

Exhibit 99.2 1 Merit Medical Investor Call February 28, 2024 Fourth Quarter 2023 Results Fred Lampropoulos Chairman and CEO Raul Parra CFO 2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation and any accompanying management commentary include “forward-looking statements,” as defined within applicable securities laws and regulations. All statements in this presentation, oth

Policy Relating to the Recovery of Erroneously Awarded Compensation.*†

Exhibit 97 MERIT MEDICAL SYSTEMS, INC. EXECUTIVE INCENTIVE COMPENSATION CLAWBACK POLICY I. Introduction The Board of Directors (the “Board”) of Merit Medical Systems, Inc., a Utah corporation (the “Company”), believes that it is in the best interests of the Company and its shareholders to create and maintain a culture that emphasizes integrity and accountability and to require the recovery of cert

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2023 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 0-18592 MERIT M

MERIT MEDICAL REPORTS RESULTS FOR FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2023 ISSUES FISCAL YEAR 2024 GUIDANCE

Exhibit 99.1 Contacts: PR/Media Inquiries: Teresa Johnson Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC Westwicke – ICR +1-801-208-4295 +1-443-213-0509 [email protected] [email protected] FOR IMMEDIATE RELEASE MERIT MEDICAL REPORTS RESULTS FOR FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2023 ISSUES FISCAL YEAR 2024 GUIDANCE ● Q4 2023 reported revenue of $324.5 million, up 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 28, 2024 Merit Medical S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 28, 2024 Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of (Commission (I.R.S. Employ

MMSI / Merit Medical Systems, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01441-meritmedicalsystemsi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 14)* Name of issuer: Merit Medical Systems Inc Title of Class of Securities: Common Stock CUSIP Number: 589889104 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box

MMSI / Merit Medical Systems, Inc. / WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC - SC 13G/A Passive Investment

SC 13G/A 1 tm245766d7sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 3)* Merit Medical Systems Inc (Name of Issuer) Common Stock (Title of Class of Securities) 589889104 (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 8, 2024 Merit Medical Sys

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): January 8, 2024 Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of (Commission (I.R.S. Employer

MERIT MEDICAL ANNOUNCES PROJECTED PRELIMINARY UNAUDITED REVENUE FOR THE YEAR ENDED DECEMBER 31, 2023 AND PLANS TO ANNOUNCE FOURTH QUARTER AND YEAR END 2023 RESULTS AND ISSUE FISCAL YEAR 2024 GUIDANCE ON FEBRUARY 28, 2024

Exhibit 99.1 Contacts: PR/Media Inquiries: Teresa Johnson Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC Westwicke - ICR +1-801-208-4295 +1-443-213-0509 [email protected] [email protected] FOR IMMEDIATE RELEASE MERIT MEDICAL ANNOUNCES PROJECTED PRELIMINARY UNAUDITED REVENUE FOR THE YEAR ENDED DECEMBER 31, 2023 AND PLANS TO ANNOUNCE FOURTH QUARTER AND YEAR END 2023 RESULTS A

December 11, 2023

December 11, 2023 Securities and Exchange Commission Division of Corporate Finance Disclosure Review Program 100 F Street, NE Washington, D.

Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 5, 2023 Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of (Commission (I.R.S. Employe

Form of Capped Call Confirmation.

Bidding form Exhibit 10.1 [DEALER]1 [], 2023 To: Merit Medical Systems, Inc. [1600 West Merit Parkway South Jordan, Utah 84095 Attention: [] Telephone No.: (801) 253-1600] 2 Re: [Base][Additional] Call Option Transaction3 The purpose of this letter agreement (this “Confirmation”) is to confirm the terms and conditions of the call option transaction entered into between [DEALER] (“Dealer”) and Meri

Form of 3.00% Convertible Senior Note due 2029 (included in Exhibit 10.68).*

Exhibit 4.2

Indenture, dated as of December 8, 2023, among Merit Medical Systems, Inc., and U.S. Bank Trust Company, National Association, as trustee.*

Execution Version Exhibit 4.1 MERIT MEDICAL SYSTEMS, INC. AND U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, as Trustee INDENTURE Dated as of December 8, 2023 3.00% Convertible Senior Notes due 2029 #97570240v12 TABLE OF CONTENTS Page Article 1 Definitions Section 1.01 . Definitions‌1 Section 1.02 . References to Interest‌14 Article 2 Issue, Description, Execution, Registration and Exchange of Not

Regulation FD Disclosure, Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 5, 2023 Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of (Commission (I.R.S. Employe

election, in respect of the remainder, if any, of Merit’s conversion obligation in excess of the aggregate principal amount of the notes being converted. In connection with the pricing of the notes, Merit entered into privately negotiated capped call

Exhibit 99.1 Merit Medical Announces Pricing of Upsized Private Offering of $650.0 Million of 3.00% Convertible Senior Notes Due 2029 SOUTH JORDAN, Utah, December 6, 2023 – Merit Medical Systems, Inc. (Nasdaq: MMSI) (“Merit”), a leading global manufacturer and marketer of healthcare technology, announced the pricing of $650.0 million aggregate principal amount of 3.00% Convertible Senior Notes due

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): December 4, 2023 Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of (Commission (I.R.S. Employe

Forward-Looking Statements This release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All st

Exhibit 99.1 Merit Medical Announces Proposed Private Placement of $550 Million of Convertible Senior Notes SOUTH JORDAN, Utah, December 4, 2023 – Merit Medical Systems, Inc. (Nasdaq: MMSI) (“Merit”), a leading global manufacturer and marketer of healthcare technology, announced today that it intends to offer, subject to market conditions and other factors, $550.0 million aggregate principal amoun

2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation and any accompanying management commentary include “forward-looking statements,” as defined within applicable securities laws and regulations. All statements in this presen

Exhibit 99.2 1 Merit Medical Investor Call October 26, 2023 Third Quarter 2023 Results Fred Lampropoulos Chairman and CEO Raul Parra CFO 2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation and any accompanying management commentary include “forward-looking statements,” as defined within applicable securities laws and regulations. All statements in this presentation, other

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 0-18592

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 26, 2023 Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of (Commission (I.R.S. Employe

MERIT MEDICAL REPORTS RESULTS FOR THIRD QUARTER ENDED SEPTEMBER 30, 2023

Exhibit 99.1 Contacts: PR/Media Inquiries: Teresa Johnson Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC Westwicke - ICR +1-801-208-4295 +1-443-213-0509 [email protected] [email protected] FOR IMMEDIATE RELEASE MERIT MEDICAL REPORTS RESULTS FOR THIRD QUARTER ENDED SEPTEMBER 30, 2023 ● Q3 2023 reported revenue of $315.2 million, up 9.8% year-over-year ● Q3 2023 constant curr

Form of Restricted Stock Unit Award Agreement, dated May 18, 2023, by and between Merit Medical Systems, Inc. and each of the following individuals: A. Scott Anderson, Lonny J. Carpenter, Stephen C. Evans, David K. Floyd, Thomas J. Gunderson, Laura S. Kaiser, Michael R. McDonnell, F. Ann Millner, and Lynne N. Ward.*†

Exhibit 10.1 MERIT MEDICAL SYSTEMS, INC 2018 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT This Restricted Stock Unit Award Agreement (this “Award Agreement”), dated effective as May 18, 2023 (the “Grant Date”), is made by and between Merit Medical Systems, Inc. (the “Company”), and , a director of the Company (“you”). 1. Award of Restricted Stock Units The Company hereby grants t

Fourth Amended and Restated Credit Agreement, dated June 6, 2023, by and among Merit Medical Systems, Inc. as Borrower and the Lenders referred to therein, as Lenders, and Wells Fargo Bank, National Association, as Administrative Agent, and Wells Fargo Securities, LLC, BOFA Securities, Inc., HSBC Bank USA, National Association, U.S. Bank National Association and Truist Securities, Inc., as Joint Lead Arrangers and Joint Bookrunners, and Bank of America, N.A., HSBC Bank USA, National Association, U.S Bank National Association and Truist Bank as Co-Syndication Agents and TD Bank, N.A., as Documentation Agent.*

Exhibit 10.2 $850,000,000 FOURTH AMENDED AND RESTATED CREDIT AGREEMENT dated as of June 6, 2023 by and among MERIT MEDICAL SYSTEMS, INC., as Borrower, the Lenders referred to herein, as Lenders, and WELLS FARGO BANK, NATIONAL ASSOCIATION, as Administrative Agent WELLS FARGO SECURITIES, LLC, BOFA SECURITIES, INC., HSBC BANK USA, NATIONAL ASSOCIATION U.S. BANK NATIONAL ASSOCIATION and TRUIST SECURIT

Asset Purchase Agreement by and between Merit Medical Systems, Inc. and AngioDynamics, Inc. dated as of June 8, 2023.*

Exhibit 10.3 ASSET PURCHASE AGREEMENT BY AND BETWEEN MERIT MEDICAL SYSTEMS, INC. AND ANGIODYNAMICS, INC. Dated as of June 8, 2023 TABLE OF CONTENTS Article 1 THE TRANSACTIONs 1.1Purchased Assets‌1 1.2Excluded Assets‌2 1.3Assumed Liabilities‌3 1.4Excluded Liabilities‌4 1.5Non-Assignable Assets‌5 1.6Shared Contracts‌6 Article 2 CONSIDERATION FOR TRANSFER 2.1Purchase Price and Assumption of Assumed L

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 0-18592 MERI

2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation and any accompanying management commentary include “forward-looking statements,” as defined within applicable securities laws and regulations. All statements in this presen

Exhibit 99.2 1 Merit Medical Investor Call July 25, 2023 Second Quarter 2023 Results Fred Lampropoulos Chairman and CEO Raul Parra CFO 2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation and any accompanying management commentary include “forward-looking statements,” as defined within applicable securities laws and regulations. All statements in this presentation, other t

MERIT MEDICAL REPORTS RESULTS FOR SECOND QUARTER JUNE 30, 2023

Exhibit 99.1 Contacts: PR/Media Inquiries: Teresa Johnson Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC Westwicke - ICR +1-801-208-4295 +1-443-213-0509 [email protected] [email protected] FOR IMMEDIATE RELEASE MERIT MEDICAL REPORTS RESULTS FOR SECOND QUARTER JUNE 30, 2023 ● Q2 2023 reported revenue of $320.1 million, up 8.5% year-over-year ● Q2 2023 constant currency reven

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 25, 2023 Merit Medical Syste

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 25, 2023 Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of (Commission (I.R.S. Employer i

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K ☒ Annual Report Pursuant to Section 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 ☐ Transition Report Pursuant to Section 15(

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K ☒ Annual Report Pursuant to Section 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 OR ☐ Transition Report Pursuant to Section 15(d) of the Securities Exchange Act of 1934 For the transition period from to Commission File Number: 000-18592 A. Full title of the plan and the add

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 8, 2023 Merit Medical System

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 8, 2023 Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of (Commission (I.R.S. Employer in

1 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Statements contained in this presentation which are not purely historical, including, without limitation, statements regarding Merit’s forecasted plans, revenues, net sales, net income (GAAP

Exhibit 99.2 0 Merit Medical Announces Acquisition of Dialysis Catheter Portfolio and the BioSentry® Biopsy Tract Sealant System from AngioDynamics, Inc. and Acquisition of the Surfacer® Inside-Out® Access Catheter System from Bluegrass Vascular Technologies, Inc. June 8, 2023 1 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Statements contained in this presentation which are not purely

AMENDED AND RESTATED EMPLOYMENT AGREEMENT

Exhibit 99.3 AMENDED AND RESTATED EMPLOYMENT AGREEMENT THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into by and between Merit Medical Systems, Inc., a Utah corporation (the “Company”) and Fred P. Lampropoulos (the “Executive”), as of the 8th day of June, 2023 (the “Effective Date”). RECITALS: WHEREAS, the Executive currently serves as the Chief Executive Off

Merit Medical Announces New Five-Year Senior Secured Credit Agreement

Merit Medical Announces New Five-Year Senior Secured Credit Agreement Credit agreement includes a revolving credit facility of up to $700 million and a term loan facility of up to $150 million SOUTH JORDAN, Utah, June 7, 2023 (GLOBE NEWSWIRE) - Merit Medical Systems, Inc.

PR/Media Inquiries:

‌ Exhibit 99.1 Contacts: PR/Media Inquiries: Sarah Comstock Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC Westwicke - ICR +1-801-432-2864 +1-443-213-0509 [email protected] [email protected] Merit Medical Announces Acquisition of Dialysis Catheter Portfolio and the BioSentry® Biopsy Tract Sealant System from AngioDynamics, Inc. and Acquisition of the Surfacer® Inside-

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 7, 2023 Merit Medical System

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 7, 2023 Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of (Commission (I.R.S. Employer in

Exhibit 1.01 - Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form.

CONFLICT MINERALS REPORT MERIT MEDICAL SYSTEMS, INC. YEAR ENDED DECEMBER 31, 2022 This Conflict Minerals Report (this “Report”) for the year ended December 31, 2022, is presented by Merit Medical Systems, Inc. (“Merit”) to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the “Rule”). The Rule was adopted by the Securities and Exchange Commission (“SEC”) to implement reporting and

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report MERIT MEDICAL SYSTEMS, INC. (Exact name of the registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) 1600 West Merit Parkway, South Jordan, Utah 84095 (Address of principal e

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 18, 2023 Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of (Commission (I.R.S. Employer in

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 0-18592 MER

Form of Performance Stock Unit Award Agreement (Three Year Performance Period), dated February 28, 2023, by and between Merit Medical Systems, Inc. and each of the following individuals: Raul Parra, Neil Peterson, Brian G. Lloyd, Michel J. Voigt, and Joseph C. Wright.*†

Exhibit 10.2 MERIT MEDICAL SYSTEMS, INC 2018 LONG-TERM INCENTIVE PLAN Performance Stock Unit Award Agreement (Three Year Performance Period) This Performance Stock Unit Award Agreement (this “Award Agreement”), dated as of February 28, 2023 (the “Grant Date”), is made by and between Merit Medical Systems, Inc. (the “Company”), and , an employee of the Company (“you”). 1. Award of Performance Stock

Performance Stock Unit Award Agreement (Three Year Performance Period), dated February 28, 2023, by and between Merit Medical Systems, Inc. and Fred Lampropoulos.*†

Exhibit 10.1 MERIT MEDICAL SYSTEMS, INC 2018 LONG-TERM INCENTIVE PLAN Performance Stock Unit Award Agreement (Three Year Performance Period) This Performance Stock Unit Award Agreement (this “Award Agreement”), dated as of February 28, 2023 (the “Grant Date”), is made by and between Merit Medical Systems, Inc. (the “Company”), and Fred Lampropoulos, an employee of the Company (“you”). 1. Award of

2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation and any accompanying management commentary include “forward-looking statements,” as defined within applicable securities laws and regulations. All statements in this presen

Exhibit 99.2 1 Merit Medical Investor Call April 26, 2023 First Quarter 2023 Results Fred Lampropoulos Chairman and CEO Raul Parra CFO 2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation and any accompanying management commentary include “forward-looking statements,” as defined within applicable securities laws and regulations. All statements in this presentation, other t

MERIT MEDICAL REPORTS RESULTS FOR FIRST QUARTER MARCH 31, 2023

Exhibit 99.1 Contacts: PR/Media Inquiries: Teresa Johnson Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC Westwicke - ICR +1-801-208-4295 +1-443-213-0509 [email protected] [email protected] FOR IMMEDIATE RELEASE MERIT MEDICAL REPORTS RESULTS FOR FIRST QUARTER MARCH 31, 2023 ● Q1 2023 reported revenue of $297.6 million, up 8.0% compared to Q1 2022 ● Q1 2023 constant currency

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 26, 2023 Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of (Commission (I.R.S. Employer

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [x] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. XX)

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. XX) Filed by the Registrant [x] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted

2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation and any accompanying management commentary include “forward-looking statements,” as defined within applicable securities laws and regulations. All statements in this presen

EX-99.2 3 mmsi-20230228xex99d2.htm EX-99.2 Exhibit 99.2 1 Merit Medical Investor Call February 22, 2023 Fourth Quarter 2022 Results Fred Lampropoulos Chairman and CEO Raul Parra CFO 2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation and any accompanying management commentary include “forward-looking statements,” as defined within applicable securities laws and regulation

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A AMENDMENT NO. 1 TO CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 22,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A AMENDMENT NO. 1 TO CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 22, 2023 Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of (Comm

MERIT MEDICAL REPORTS RESULTS FOR FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2022 ISSUES FISCAL YEAR 2023 GUIDANCE

Exhibit 99.1 Contacts: PR/Media Inquiries: Teresa Johnson Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC Westwicke - ICR +1-801-208-4295 +1-443-213-0509 [email protected] [email protected] FOR IMMEDIATE RELEASE MERIT MEDICAL REPORTS RESULTS FOR FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2022 ISSUES FISCAL YEAR 2023 GUIDANCE ● Q4 2022 reported revenue of $293.4 million, up 5

Employment Agreement between Merit Medical Systems, Inc. and Neil Peterson, dated May 19, 2022.*†

Exhibit 10.51 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the “Agreement”) is made and entered into by and between Merit Medical Systems, Inc., a Utah corporation (the “Company”) and Neil Peterson (the “Executive”), effective May 19, 2022. RECITALS: WHEREAS, the Executive currently serves as an executive employee of the Company; and WHEREAS, the Board of Directors of the Company (the “Board”)

Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

EXHIBIT 4.2 DESCRIPTION OF THE REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Merit Medical Systems, Inc. (“Merit” “we” “us” or “our”) has one class of securities, our common stock, registered under Section 12 of the Securities Exchange Act of 1934, as amended. The general terms and provisions of our common stock are summarized below. The below sum

Subsidiaries of Merit Medical Systems, Inc.

Exhibit 21 SUBSIDIARIES OF MERIT MEDICAL SYSTEMS, INC. Subsidiary Name Jurisdiction of Incorporation/Organization Merit Medical Australia Pty Ltd. Australia ITL Healthcare Pty Ltd. Australia Merit Medical Austria GmbH Austria Merit Medical Belgium Sprl Belgium Merit Medical Comercialização, Distribuição, Importação e Exportação de Produtos Hospitalares LTDA. Brazil Merit Medical Canada Ltd. Canada

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2022 or ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from to . Commission File Number 0-18592 MERIT M

Form of Restricted Stock Unit Award Agreement, dated May 24, 2022, by and between Merit Medical Systems, Inc. and each of the following individuals: A. Scott Anderson, Lonny J. Carpenter, Stephen C. Evans, David K. Floyd, James T. Hogan, Thomas J. Gunderson, Laura s. Kaiser, Michael R. McDonnell, F. Ann Millner, and Lynne N. Ward.*†

Exhibit 10.60 MERIT MEDICAL SYSTEMS, INC 2018 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT This Restricted Stock Unit Award Agreement (this “Award Agreement”), dated effective as of May 24, 2022 (the “Grant Date”), is made by and between Merit Medical Systems, Inc. (the “Company”), and [], a director of the Company (“you”). 1. Award of Restricted Stock Units The Company hereby gr

Second Amendment to Lease Agreement dated March 10, 2022, by and between MM (UT) QRS 11-59, Inc. and Merit Medical Systems, Inc. for office and manufacturing facility.*

Exhibit 10.61 SECOND AMENDMENT TO LEASE AGREEMENT THIS SECOND AMENDMENT TO LEASE AGREEMENT (this "Amendment") dated as of l\'ltlCR JO, 2022 (the "Effective Date") by and between MM (UT) QRS 11-59, INC., a Delaware corporation ("Landlord"), as lessor, and MERIT MEDICAL SYSTEMS, INC., a Utah corporation ("Tenant"), as lessee. -W I TN E S S E T H: - WHEREAS, QRS 11-20 (UT), INC., a Utah corporation (

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 22, 2023 Merit Medical S

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 22, 2023 Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of (Commission (I.R.S. Employ

Conference Call Presentation.

1 Merit Medical Investor Call February 22, 2023 Fourth Quarter 2022 Results Fred Lampropoulos Chairman and CEO Raul Parra CFO2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation and any accompanying management commentary include “forward-looking statements,” as defined within applicable securities laws and regulations.

MERIT MEDICAL REPORTS RESULTS FOR FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2022 ISSUES FISCAL YEAR 2023 GUIDANCE

Exhibit 99.1 Contacts: PR/Media Inquiries: Teresa Johnson Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC Westwicke - ICR +1-801-208-4295 +1-443-213-0509 [email protected] [email protected] FOR IMMEDIATE RELEASE MERIT MEDICAL REPORTS RESULTS FOR FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2022 ISSUES FISCAL YEAR 2023 GUIDANCE ● Q4 2022 reported revenue of $293.4 million, up 5

MMSI / Merit Medical Systems, Inc. / ArrowMark Colorado Holdings LLC Passive Investment

SC 13G/A 1 arrowmark-mmsi123122a3.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Merit Medical Systems, Inc. (Name of Issuer) Common Stock, no par (Title of Class of Securities) 589889104 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriat

MMSI / Merit Medical Systems, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SC 13G/A 1 tv01408-meritmedicalsystemsi.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 13)* Name of issuer: Merit Medical Systems Inc. Title of Class of Securities: Common Stock CUSIP Number: 589889104 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate bo

MMSI / Merit Medical Systems, Inc. / WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2)* Merit Medical Systems Inc (Name of Issuer) Common Stock (Title of Class of Securities) 589889104 (CUSIP Number) December 31, 2022 (Date of

Summary Notice to Current Merit Medical Systems, Inc. Stockholders of Derivative Action and Settlement Hearing TO: ALL OWNERS OF MERIT MEDICAL SYSTEMS, INC. (“MERIT” OR THE “COMPANY”) COMMON STOCK AS OF AUGUST 17, 2022 (“CURRENT MERIT STOCKHOLDERS”)

Exhibit 99.2 Summary Notice to Current Merit Medical Systems, Inc. Stockholders of Derivative Action and Settlement Hearing TO: ALL OWNERS OF MERIT MEDICAL SYSTEMS, INC. (?MERIT? OR THE ?COMPANY?) COMMON STOCK AS OF AUGUST 17, 2022 (?CURRENT MERIT STOCKHOLDERS?) YOU ARE HEREBY NOTIFIED that the parties to the above-captioned stockholder derivative action, Maute v. Lampropoulos et al., Civ. Case No

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 2, 2022 Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of (Commission (I.R.S. Employe

IN THE UNITED STATES DISTRICT COURT DISTRICT OF UTAH

Exhibit 99.1 IN THE UNITED STATES DISTRICT COURT DISTRICT OF UTAH STEFFEN MAUTE, derivatively on behalf of MERIT MEDICAL SYSTEMS, INC., Plaintiff, SUMMARY NOTICE TO CURRENT MERIT MEDICAL SYSTEMS, INC. vs. STOCKHOLDERS OF DERIVATIVE ACTION AND SETTLEMENT FRED P. LAMPROPOULOS; RAUL HEARING PARRA; A. SCOTT ANDERSON; JILL D. ANDERSON; THOMAS J. GUNDERSON; F. ANN MILLNER; LYNNE N. WARD; and JUSTIN F. L

Indemnification Agreement, dated as of June 17, 2021, between Merit Medical Systems, Inc. and Stephen C. Evans.*†

Exhibit 10.1 INDEMNIFICATION AGREEMENT This Indemnification Agreement (the “Agreement”) is made as of June 17, 2021, by and between Merit Medical Systems, Inc., a Utah corporation (“Company”), and Stephen Evans, an individual (“Indemnitee”). RECITALS A.The Company is aware that because of the increased exposure to litigation costs, talented and experienced persons are increasingly reluctant to ser

Form of Indemnification Agreement, dated as of May 19, 2022, between Merit Medical Systems, Inc. and each of Laura Kaiser and Michael McDonnell.*†

EX-10.2 3 mmsi-20220930xex10d2.htm EX-10.2 Exhibit 10.2 INDEMNIFICATION AGREEMENT This Indemnification Agreement (the “Agreement”) is made as of May 19, 2022, by and between Merit Medical Systems, Inc., a Utah corporation (“Company”), and [Name], an individual (“Indemnitee”). RECITALS A.The Company is aware that because of the increased exposure to litigation costs, talented and experienced person

Indemnification Agreement, dated as of October 22, 2022, between the Company and Neil Peterson †

Exhibit 10.3 INDEMNIFICATION AGREEMENT This Indemnification Agreement (the “Agreement”) is made as of October 22, 2022, by and between Merit Medical Systems, Inc., a Utah corporation (“Company”), and Neil Peterson, an individual (“Indemnitee”). RECITALS A.The Company is aware that because of the increased exposure to litigation costs, talented and experienced persons are increasingly reluctant to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents d Peripheral Intervention engu%911Y2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 26, 2022 ? ? Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Utah 0-18592 87-0447695 (State or other jurisdiction of

2 CAUTIONARY STATEMENTREGARDING FORWARD-LOOKING STATEMENTS Thispresentationandanyaccompanyingmanagementcommentaryinclude“forward-lookingstatements,”asdefinedwithinapplicablesecuritieslawsandregulations.Allstatementsinthis presentation,otherthanstatem

Exhibit 99.2 1 Merit Medical Investor Call October 26, 2022 Third Quarter 2022 Results Fred Lampropoulos Chairman and CEO Raul Parra CFO 2 CAUTIONARY STATEMENTREGARDING FORWARD-LOOKING STATEMENTS Thispresentationandanyaccompanyingmanagementcommentaryinclude?forward-lookingstatements,?asdefinedwithinapplicablesecuritieslawsandregulations.Allstatementsinthis presentation,otherthanstatementsofhistori

MERIT MEDICAL REPORTS RESULTS FOR QUARTER ENDED SEPTEMBER 30, 2022

Exhibit 99.1 ? ? ? ? ? ? ? ? ? ? ? ? ? ? Contacts: ? ? ? ? ? ? PR/Media Inquiries: Teresa Johnson Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC Westwicke - ICR ? ? ? ? +1-801-208-4295 +1-443-213-0509 ? ? ? ? [email protected] [email protected] ? ? ? ? ? ? ? ? FOR IMMEDIATE RELEASE MERIT MEDICAL REPORTS RESULTS FOR QUARTER ENDED SEPTEMBER 30, 2022 ? ? Q3 2022 reported reven

Separation Agreement dated as of August 26, 2022, by and between Ron Frost and Merit Medical Systems, Inc.

Exhibit 10.1 This document affects your legal rights. You are advised to consult with an attorney or other counsel of your choice prior to signing this Agreement. SEPARATION AGREEMENT AND RELEASE OF ALL CLAIMS THIS SEPARATION AGREEMENT AND RELEASE OF ALL CLAIMS (the ?Agreement?) is entered into between Merit Medical Systems, Inc., a Utah corporation (?Employer?) and Ron Frost (?Employee?)(Employer

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A AMENDMENT NO. 1 TO CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 19, 2022 Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of (Commiss

Performance Stock Unit Award Agreement (Three Year Performance Period), dated May 19, 2022, by and between Merit Medical Systems, Inc. and Neil Peterson.*†

Exhibit 10.2 MERIT MEDICAL SYSTEMS, INC 2018 LONG-TERM INCENTIVE PLAN Performance Stock Unit Award Agreement (Three Year Performance Period) This Performance Stock Unit Award Agreement (this ?Award Agreement?), dated as of May 19, 2022 (the ?Grant Date?), is made by and between Merit Medical Systems, Inc. (the ?Company?), and Neil Peterson, an employee of the Company (?you?). 1.Award of Performanc

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents dengu%911Y2022 ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Deferred Compensation Plan for Non-Employee Directors, effective as of July 22, 2022.*†

Exhibit 10.1 MERIT MEDICAL SYSTEM, INC. DEFERRED COMPENSATION PLAN FOR NON-EMPLOYEE DIRECTORS (As adopted effective July 22, 2022) Section 1. Adoption and Effective Date On July 22, 2022, Merit Medical Systems, Inc., a Utah corporation (the ?Company?) adopted this Merit Medical Systems, Inc. Deferred Compensation Plan for Non-Employee Directors (the ?Plan?) with the approval of the Company?s Board

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 27, 2022 ? ? Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Utah 0-18592 87-0447695 (State or other jurisdiction of ?

MERIT MEDICAL REPORTS RESULTS FOR QUARTER ENDED JUNE 30, 2022

Exhibit 99.1 ? ? ? ? ? ? ? ? ? ? ? ? ? ? Contacts: ? ? ? ? ? ? PR/Media Inquiries: Teresa Johnson Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC Westwicke - ICR ? ? ? ? +1-801-208-4295 +1-443-213-0509 ? ? ? ? [email protected] [email protected] ? ? ? ? ? ? ? ? FOR IMMEDIATE RELEASE MERIT MEDICAL REPORTS RESULTS FOR QUARTER ENDED JUNE 30, 2022 ? ? Q2 2022 reported revenue of

2 CAUTIONARY STATEMENT REGARDING FORWARD - LOOKING STATEMENTS This presentation and any accompanying management commentary include “forward - looking statements,” as defined within applicable securities laws and regulations . All statements in this p

Exhibit 99.2 1 Merit Medical Investor Call July 27, 2022 Second Quarter 2022 Results Fred Lampropoulos Chairman and CEO Raul Parra CFO 2 CAUTIONARY STATEMENT REGARDING FORWARD - LOOKING STATEMENTS This presentation and any accompanying management commentary include ?forward - looking statements,? as defined within applicable securities laws and regulations .. All statements in this presentation, o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K ☒ Annual Report Pursuant to Section 15(d) of the Securities Exchange Act of 1934 For the fiscal year ended December 31, 2021 ☐ Transition Report Pursuant to Section 15(

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 11-K ? ? ? Annual Report Pursuant to Section 15(d) of the Securities Exchange Act of 1934 ? For the fiscal year ended December 31, 2021 ? OR ? ? Transition Report Pursuant to Section 15(d) of the Securities Exchange Act of 1934 ? For the transition period from to ? Commission File Number: 000-18592 ? A. Full title o

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report MERIT MEDICAL SYSTEMS, INC. (Exact name of the registrant as specified in its charter) ? ? Utah 0-18592 87-0447695 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) ? 1600 West Merit Parkway, South Jordan, Utah 84095 (Address of pri

Exhibit 1.01 - Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form.

CONFLICT MINERALS REPORT MERIT MEDICAL SYSTEMS, INC. YEAR ENDED DECEMBER 31, 2021 ? This Conflict Minerals Report (this ?Report?) for the year ended December 31, 2021, is presented by Merit Medical Systems, Inc. (?Merit?) to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the ?Rule?). The Rule was adopted by the Securities and Exchange Commission (?SEC?) to implement reporting an

Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): May 19, 2022 ? ? Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Utah 0-18592 87-0447695 (State or other jurisdiction of ? (

Form of Performance Stock Unit Award Agreement (Three Year Performance Period), dated February 26, 2022, by and between Merit Medical Systems, Inc. and each of the following individuals: Brian G. Lloyd, Michel J. Voigt, and Joseph C. Wright.*†

? ? MERIT MEDICAL SYSTEMS, INC 2018 LONG-TERM INCENTIVE PLAN Performance Stock Unit Award Agreement (Three Year Performance Period) This Performance Stock Unit Award Agreement (this ?Award Agreement?), dated as of February 26, 2022 (the ?Grant Date?), is made by and between Merit Medical Systems, Inc.

Performance Stock Unit Award Agreement (Three Year Performance Period), dated February 26, 2022, by and between Merit Medical Systems, Inc. and Fred Lampropoulos.*†

? ? MERIT MEDICAL SYSTEMS, INC 2018 LONG-TERM INCENTIVE PLAN Performance Stock Unit Award Agreement (Three Year Performance Period) This Performance Stock Unit Award Agreement (this ?Award Agreement?), dated as of February 26, 2022 (the ?Grant Date?), is made by and between Merit Medical Systems, Inc.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents de ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Performance Stock Unit Award Agreement (Three Year Performance Period), dated February 26, 2022, by and between Merit Medical Systems, Inc. and Raul Parra.*†

? ? MERIT MEDICAL SYSTEMS, INC 2018 LONG-TERM INCENTIVE PLAN Performance Stock Unit Award Agreement (Three Year Performance Period) This Performance Stock Unit Award Agreement (this ?Award Agreement?), dated as of February 26, 2022 (the ?Grant Date?), is made by and between Merit Medical Systems, Inc.

MERIT MEDICAL REPORTS RESULTS FOR QUARTER ENDED MARCH 31, 2022

Exhibit 99.1 ? ? ? ? ? ? ? ? ? ? ? ? ? ? Contacts: ? ? ? ? ? ? PR/Media Inquiries: Teresa Johnson Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC Westwicke - ICR ? ? ? ? +1-801-208-4295 +1-443-213-0509 ? ? ? ? [email protected] [email protected] ? ? ? ? ? ? ? ? FOR IMMEDIATE RELEASE MERIT MEDICAL REPORTS RESULTS FOR QUARTER ENDED MARCH 31, 2022 ? ? Q1 2022 reported revenue o

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 27, 2022 ? ? Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Utah 0-18592 87-0447695 (State or other jurisdiction of ?

2 CAUTIONARY STATEMENT REGARDING FORWARD - LOOKING STATEMENTS This presentation and any accompanying management commentary include “forward - looking statements,” as defined within applicable securities laws and regulations . All statements in this p

Exhibit 99..2 1 Merit Medical Investor Call April 27, 2022 First Quarter 2022 Results Fred Lampropoulos Chairman and CEO Raul Parra CFO 2 CAUTIONARY STATEMENT REGARDING FORWARD - LOOKING STATEMENTS This presentation and any accompanying management commentary include ?forward - looking statements,? as defined within applicable securities laws and regulations .. All statements in this presentation,

1

Exhibit 99.1 ? ? Merit Medical Announces Chief Operating Officer Transition? Ronald A. Frost to Retire After More than 30 Years of Service Neil Peterson, a 27-Year Company Veteran, Appointed COO SOUTH JORDAN, Utah, April 21, 2022 (GLOBE NEWSWIRE) - Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that Chief Operating O

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Other Events

? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 19, 2022 ? ? Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Utah 0-18592 87-0447695 (State or other jurisdiction of ?

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) ? Filed by the Registrant [x] ? Filed by a Party other than the Registrant [ ] ? Check the appropriate box: ? ? [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 ? Filed by the Registrant [x] ? Filed by a Party other than the Registrant [ ] ? Check the appropriate box: ? ? [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 1

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [x] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Subsidiaries of Merit Medical Systems, Inc.

? Exhibit 21 ? ? SUBSIDIARIES OF MERIT MEDICAL SYSTEMS, INC. ? ? Subsidiary Name Jurisdiction of Incorporation/Organization Merit Medical Australia Pty Ltd. Australia ITL Healthcare Pty Ltd. Australia Merit Medical Austria GmbH Austria Merit Medical Belgium Sprl Belgium Merit Medical Comercializa??o, Distribui??o, Importa??o e Exporta??o de Produtos Hospitalares LTDA. Brazil Merit Medical Canada L

Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

EXHIBIT 4.2 ? DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 ? Merit Medical Systems, Inc. (?Merit? ?we? ?us? or ?our?) has one class of securities, our common stock, registered under Section 12 of the Securities Exchange Act of 1934, as amended. ? The general terms and provisions of our common stock are summarized below. The bel

1 Merit Medical Investor Call February 24, 2022 2021 Results and 2022 Guidance Fred Lampropoulos Chairman and CEO Raul Parra CFO 2 CAUTIONARY STATEMENT REGARDING FORWARD - LOOKING STATEMENTS This presentation and any accompanying management commentar

Exhibit 99.2 1 Merit Medical Investor Call February 24, 2022 2021 Results and 2022 Guidance Fred Lampropoulos Chairman and CEO Raul Parra CFO 2 CAUTIONARY STATEMENT REGARDING FORWARD - LOOKING STATEMENTS This presentation and any accompanying management commentary include ?forward - looking statements,? as defined within applicable securities laws and regulations .. All statements in this presenta

MERIT MEDICAL REPORTS RESULTS FOR FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2021, ISSUES FY 2022 GUIDANCE

Exhibit 99.1 ? ? ? ? ? ? ? ? ? ? ? ? ? ? Contacts: ? ? ? ? ? ? PR/Media Inquiries: Teresa Johnson Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC Westwicke - ICR ? ? ? ? +1-801-208-4295 +1-443-213-0509 ? ? ? ? [email protected] [email protected] ? ? ? ? ? ? ? ? FOR IMMEDIATE RELEASE MERIT MEDICAL REPORTS RESULTS FOR FOURTH QUARTER AND YEAR ENDED DECEMBER 31, 2021, ISSUES FY

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): February 24, 2022 ? ? Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Utah 0-18592 87-0447695 (State or other jurisdiction o

MMSI / Merit Medical Systems, Inc. / ArrowMark Colorado Holdings LLC Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.

MMSI / Merit Medical Systems, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 12)* Name of issuer: Merit Medical Systems Inc. Title of Class of Securities: Common Stock CUSIP Number: 589889104 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is

MMSI / Merit Medical Systems, Inc. / WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC - SC 13G/A Passive Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2 (Amendment No. 1)* Merit Medical Systems Inc (Name of Issuer) Common Stock (Title of Class of Securities) 589889104 (CUSIP Number) December 31, 2021 (Date of

As filed with the Securities and Exchange Commission on January 13, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under the Securities Act of 1933 MERIT MEDICAL SYSTEMS, INC. (Exact name

As filed with the Securities and Exchange Commission on January 13, 2022 ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

As filed with the Securities and Exchange Commission on January 13, 2022 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT Under the Securities Act of 1933 MERIT MEDICAL SYSTEMS, INC. (Exact name

As filed with the Securities and Exchange Commission on January 13, 2022 ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Financial Statements and Exhibits, Other Events

? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): November 23, 2021 ? ? Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Utah 0-18592 87-0447695 (State or other jurisdiction o

MERIT MEDICAL ANNOUNCES AGREEMENT IN PRINCIPLE TO SETTLE CLASS ACTION LITIGATION

Exhibit 99.1 ? ? ? ? ? ? ? ? ? ? ? ? ? ? Contacts: ? ? ? ? ? ? PR/Media Inquiries: Teresa Johnson Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC Westwicke - ICR ? ? ? ? +1-801-208-4295 +1-443-213-0509 ? ? ? ? [email protected] [email protected] ? ? ? ? ? ? ? ? FOR IMMEDIATE RELEASE MERIT MEDICAL ANNOUNCES AGREEMENT IN PRINCIPLE TO SETTLE CLASS ACTION LITIGATION ? SOUTH JORD

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

MERIT MEDICAL REPORTS RESULTS FOR QUARTER ENDED SEPTEMBER 30, 2021

Exhibit 99.1 ? ? ? ? ? ? ? ? ? ? ? ? ? ? Contacts: ? ? ? ? ? ? PR/Media Inquiries: Teresa Johnson Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC Westwicke - ICR ? ? ? ? +1-801-208-4295 +1-443-213-0509 ? ? ? ? [email protected] [email protected] ? ? ? ? ? ? ? ? FOR IMMEDIATE RELEASE MERIT MEDICAL REPORTS RESULTS FOR QUARTER ENDED SEPTEMBER 30, 2021 ? ? Q3 2021 reported reven

1 Merit Medical Investor Call October 28, 2021 Third Quarter 2021 Results Fred Lampropoulos Chairman and CEO Raul Parra CFO 2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation and any accompanying management commentary inclu

Exhibit 99.2 1 Merit Medical Investor Call October 28, 2021 Third Quarter 2021 Results Fred Lampropoulos Chairman and CEO Raul Parra CFO 2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation and any accompanying management commentary include ?forward-looking statements,? as defined within applicable securities laws and regulations. All statements in this presentation, other

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 28, 2021 ? ? Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Utah 0-18592 87-0447695 (State or other jurisdiction of

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits

? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): October 19, 2021 ? ? Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Utah 0-18592 87-0447695 (State or other jurisdiction of

MMSI / Merit Medical Systems, Inc. / Starboard Value LP - AMENDMENT NO. 4 TO THE SCHEDULE 13D Activist Investment

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(a) (Amendment No. 4)1 Merit Medical Systems, Inc. (Name of Issuer) Common Stock, no par value (Title of Class of Securities) 589889104 (CUSIP Number) JEFFREY C. SMITH STARBO

Fifth Amendment to the Merit Medical Systems, Inc., 1996 Employee Stock Purchase Plan dated April 15, 2021.*†

EXHIBIT 10.3 ? ? FIFTH AMENDMENT TO THE MERIT MEDICAL SYSTEMS, INC. 1996 EMPLOYEE STOCK PURCHASE PLAN ? ? THIS FIFTH AMENDMENT TO THE MERIT MEDICAL SYSTEMS, INC. 1996 EMPOLOYEE STOCK PURCHASE PLAN (this "Amendment") is made and adopted effective April 15, 2021 by Merit Medical Systems, Inc., contingent upon approval of this Amendment by the shareholders of the Company not later than June 30, 2021.

Second Amendment to the Merit Medical Systems, Inc. 2018 Long-Term Incentive Plan effective April 15, 2021.*†

EXHIBIT 10.2 ? ? SECOND AMENDMENT TO THE MERIT MEDICAL SYSTEMS, INC. 2018 LONG-TERM INCENTIVE PLAN ? ? THIS SECOND AMENDMENT TO THE MERIT MEDICAL SYSTEMS, INC. 2018 LONG-TERM INCENTIVE PLAN (this ?Amendment?) is made and adopted effective April 15, 2021 by Merit Medical Systems, Inc., contingent upon approval of this Amendment by the shareholders of the Company not later than June 30, 2021. ? WHER

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Form of Restricted Stock Unit Award Agreement, dated June 17, 2021, by and between Merit Medical Systems, Inc. and each of the following individuals: A. Scott Anderson, Jill D. Anderson, Lonny J. Carpenter, Stephen C. Evans, David K. Floyd, James T. Hogan, Thomas J. Gunderson, F. Ann Millner, and Lynne N. Ward. *†

EXHIBIT 10.1 ? MERIT MEDICAL SYSTEMS, INC 2018 LONG-TERM INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT ? This Restricted Stock Unit Award Agreement (this ?Award Agreement?), dated effective as of June 17, 2021 (the ?Grant Date?), is made by and between Merit Medical Systems, Inc. (the ?Company?), and [Name], a director of the Company (?you?). 1. Award of Restricted Stock Units The Company h

1 Merit Medical Investor Call July 29, 2021 Second Quarter 2021 Results Fred Lampropoulos Chairman and CEO Raul Parra CFO 2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation and any accompanying management commentary include

Exhibit 99.2 1 Merit Medical Investor Call July 29, 2021 Second Quarter 2021 Results Fred Lampropoulos Chairman and CEO Raul Parra CFO 2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation and any accompanying management commentary include ?forward-looking statements,? as defined within applicable securities laws and regulations. All statements in this presentation, other t

MERIT MEDICAL REPORTS RESULTS FOR QUARTER ENDED JUNE 30, 2021

Exhibit 99.1 ? ? ? ? ? ? ? ? ? ? ? ? ? ? Contacts: ? ? ? ? ? ? PR/Media Inquiries: Teresa Johnson Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC Westwicke - ICR ? ? ? ? +1-801-208-4295 +1-443-213-0509 ? ? ? ? [email protected] [email protected] ? ? ? ? ? ? ? ? FOR IMMEDIATE RELEASE MERIT MEDICAL REPORTS RESULTS FOR QUARTER ENDED JUNE 30, 2021 ? ? Q2 2021 reported revenue of

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): July 29, 2021 ? ? Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Utah 0-18592 87-0447695 (State or other jurisdiction of ?

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 11-K

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? ? FORM 11-K ? ? (Mark One) ? Annual Report Pursuant to Section 15(d) of the Securities Exchange Act of 1934 ? For the fiscal year ended December 31, 2020 ? OR ? ? Transition Report Pursuant to Section 15(d) of the Securities Exchange Act of 1934 ? For the transition period from to ? Commission File Number: 000-18592 ? A. Ful

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders

? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ? FORM 8-K ? CURRENT REPORT ? Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): June 17, 2021 ? ? Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) ? ? ? ? ? ? Utah 0-18592 87-0447695 (State or other jurisdiction of ?

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report

? ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report MERIT MEDICAL SYSTEMS, INC. (Exact name of the registrant as specified in its charter) ? ? Utah 0-18592 87-0447695 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) ? 1600 West Merit Parkway, South Jordan, Utah 84095 (Address

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report

? ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM SD Specialized Disclosure Report MERIT MEDICAL SYSTEMS, INC. (Exact name of the registrant as specified in its charter) ? ? Utah 0-18592 87-0447695 (State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification No.) ? 1600 West Merit Parkway, South Jordan, Utah 84095 (Address

Exhibit 1.01 - Conflict Minerals Report as required by Items 1.01 and 1.02 of this Form.

CONFLICT MINERALS REPORT MERIT MEDICAL SYSTEMS, INC. YEAR ENDED DECEMBER 31, 2020 ? This Conflict Minerals Report (this ?Report?) for the year ended December 31, 2020 is presented by Merit Medical Systems, Inc. (?Merit?) to comply with Rule 13p-1 under the Securities Exchange Act of 1934 (the ?Rule?). The Rule was adopted by the Securities and Exchange Commission (?SEC?) to implement reporting and

Performance Stock Unit Award Agreement (Three Year Performance Period), dated March 19, 2021, by and between Merit Medical Systems, Inc. and Fred Lampropoulos.*†

EXHIBIT 10.3 ? MERIT MEDICAL SYSTEMS, INC 2018 LONG-TERM INCENTIVE PLAN Performance Stock Unit Award Agreement (Three Year Performance Period) This Performance Stock Unit Award Agreement (this ?Award Agreement?), dated as of March 19, 2021 (the ?Grant Date?), is made by and between Merit Medical Systems, Inc. (the ?Company?), and Fred Lampropoulos, an employee of the Company (?you?). 1. Award of P

Form of Performance Stock Unit Award Agreement (Two Year Performance Period), dated March 19, 2021, by and between Merit Medical Systems, Inc. and each of the following individuals: Raul Parra, Brian G. Lloyd, Michel J. Voigt, and Joseph C. Wright.*†

EXHIBIT 10.4 ? MERIT MEDICAL SYSTEMS, INC 2018 LONG-TERM INCENTIVE PLAN Performance Stock Unit Award Agreement (Two Year Performance Period) This Performance Stock Unit Award Agreement (this ?Award Agreement?), dated as of March 19, 2021 (the ?Grant Date?), is made by and between Merit Medical Systems, Inc. (the ?Company?), and ? ?? ?? ?, an employee of the Company (?you?). 1. Award of Performance

Performance Stock Unit Award Agreement (Two Year Performance Period), dated March 19, 2021, by and between Merit Medical Systems, Inc. and Fred Lampropoulos.*†

EXHIBIT 10.2 ? MERIT MEDICAL SYSTEMS, INC 2018 LONG-TERM INCENTIVE PLAN Performance Stock Unit Award Agreement (Two Year Performance Period) This Performance Stock Unit Award Agreement (this ?Award Agreement?), dated as of March 19, 2021 (the ?Grant Date?), is made by and between Merit Medical Systems, Inc. (the ?Company?), and Fred Lampropoulos, an employee of the Company (?you?). 1. Award of Per

Form of Performance Stock Unit Award Agreement (Three Year Performance Period), dated March 19, 2021, by and between Merit Medical Systems, Inc. and each of the following individuals: Raul Parra, Brian G. Lloyd, Michel J. Voigt, and Joseph C. Wright.*†

EXHIBIT 10.5 ? MERIT MEDICAL SYSTEMS, INC 2018 LONG-TERM INCENTIVE PLAN Performance Stock Unit Award Agreement (Three Year Performance Period) This Performance Stock Unit Award Agreement (this ?Award Agreement?), dated as of March 19, 2021 (the ?Grant Date?), is made by and between Merit Medical Systems, Inc. (the ?Company?), and ? ?? ?? ?, an employee of the Company (?you?). 1. Award of Performan

Quarterly Report - 10-Q

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Fifth Amendment to the Merit Medical Systems, Inc. 1996 Employee Stock Purchase Plan (included as Appendix B to the Registrant’s Definitive Proxy Statement for its 2021 Annual Meeting of Stockholders filed with the Commission on April 30, 2021

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [x] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

- DEFA14A

DEFA14A 1 mmsi-20210430xdefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant [x] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commis

MERIT MEDICAL REPORTS RESULTS FOR QUARTER ENDED MARCH 31, 2021

Exhibit 99.1 ? ? ? ? ? ? ? ? ? ? ? ? ? ? Contacts: ? ? ? ? ? ? PR/Media Inquiries: Teresa Johnson Merit Medical Investor Inquiries: Mike Piccinino, CFA, IRC Westwicke - ICR ? ? ? ? +1-801-208-4295 +1-443-213-0509 ? ? ? ? [email protected] [email protected] ? ? ? ? ? ? ? ? FOR IMMEDIATE RELEASE MERIT MEDICAL REPORTS RESULTS FOR QUARTER ENDED MARCH 31, 2021 ? ? Q1 2021 reported revenue o

Regulation FD Disclosure, Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (date of earliest event reported): April 29, 2021 Merit Medical Systems, Inc. (Exact name of registrant as specified in its charter) Utah 0-18592 87-0447695 (State or other jurisdiction of (Commission (I.R.S. Employer

1 Merit Medical Investor Call April 29, 2021 First Quarter 2021 Results Fred Lampropoulos Chairman and CEO Raul Parra CFO 2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation and any accompanying management commentary include

Exhibit 99.2 1 Merit Medical Investor Call April 29, 2021 First Quarter 2021 Results Fred Lampropoulos Chairman and CEO Raul Parra CFO 2 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This presentation and any accompanying management commentary include ?forward-looking statements,? as defined within applicable securities laws and regulations. All statements in this presentation, other t

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)*

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 11)* Name of issuer: Merit Medical Systems Inc. Title of Class of Securities: Common Stock CUSIP Number: 589889104 Date of Event Which Requires Filing of this Statement: March 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is fil

Description of the Registrant's Securities Registered Pursuant to Section 12 of the Securities Exchange Act of 1934

EXHIBIT 4.2 ? DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 ? Merit Medical Systems, Inc. (?Merit? ?we? ?us? or ?our?) has one class of securities, our common stock, registered under Section 12 of the Securities Exchange Act of 1934, as amended. ? The general terms and provisions of our common stock are summarized below. The bel

Employment Agreement between the Company and Justin J. Lampropoulos, dated November 19, 2020†

Exhibit 10.52 ? ? ? MERIT MEDICAL NEDERLAND BV AGREEMENT FOR EMPLOYMENT ? The undersigned: ? A. The private company with limited liability according to Dutch law, MERIT MEDICAL NEDERLAND BV, established at and having its offices at Amerikalaan 42, 6199 AE Maastricht Airport, Netherlands, here represented by Manon van Kregten-Maarschalkerweerd, International Employment Counsel & Compliance Manager

Form of Indemnification Agreement, dated October 24, 2020, between Merit Medical Systems, Inc. and each of the following individuals: Lonny J. Carpenter, David K. Floyd, and James T. Hogan.*†

? ? Exhibit 10.50 ? ? ? INDEMNIFICATION AGREEMENT ? This Indemnification Agreement (the ?Agreement?) is made as of October 24, 2020 by and between Merit Medical Systems, Inc., a Utah corporation (?Company?), and [?], an individual (?Indemnitee?). ? RECITALS ? A.The Company is aware that because of the increased exposure to litigation costs, talented and experienced persons are increasingly relucta

Employment Agreement between Merit Medical Systems, Inc. and Michel J. Voigt, dated December 11, 2020.*†

Exhibit 10.53 EMPLOYMENT AGREEMENT THIS EMPLOYMENT AGREEMENT (the ?Agreement?) is made and entered into by and between Merit Medical Systems, Inc., a Utah corporation (the ?Company?) and Michel J. Voigt (the ?Executive?), as of December 11, 2020. RECITALS: WHEREAS, the Executive currently serves as an executive employee of the Company; and WHEREAS, the Board of Directors of the Company (the ?Board

Form of Indemnification Agreement, dated October 24, 2020, between Merit Medical Systems, Inc. and each of the following individuals: A. Scott Anderson, F. Ann Millner, Ed. D., Lynne N. Ward, and Thomas J. Gunderson.*†

Exhibit 10.49 ? ? INDEMNIFICATION AGREEMENT ? This Indemnification Agreement (the ?Agreement?) is made as of October 24, 2020 by and between Merit Medical Systems, Inc., a Utah corporation (?Company?), and [?], an individual (?Indemnitee?). ? RECITALS ? A.The Company is aware that because of the increased exposure to litigation costs, talented and experienced persons are increasingly reluctant to

Annual Report - 10-K

Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.

Subsidiaries of Merit Medical Systems, Inc.

? Exhibit 21 ? ? SUBSIDIARIES OF MERIT MEDICAL SYSTEMS, INC. as of December 31, 2020 ? ? Subsidiary Name Jurisdiction of Incorporation/Organization Merit Medical Australia Pty Ltd. Australia IntelliMedical Technologies Pty Ltd. Australia ITL Healthcare Pty Ltd. Australia Merit Medical Austria GmbH Austria Merit Medical Belgium Sprl Belgium Merit Medical Comercializa??o, Distribui??o, Importa??o e